La chaîne d'options affiche les données clés des options sur actions de Inspira Technologies Oxy à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Inspira Technologies Oxy..

Inspira Technologies Oxy (NASDAQ:IINN) Stock, Chaîne d'Options

Inspira Technologies Oxy

Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Inspira Technologies Oxy B.H.N. Ltd. - Ordinary Shares

Inspira Technologies Oxy BHN Ltd

Inspira Technologies Oxy B.H.N. Ltd. - Warrant

<p><strong>Strategy Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), a stock popularized as a proxy for <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), received mixed signals from key technical indicators Thursday.</p>
<p><strong>What happened: </strong>According to the market analytics platform TradingView, the simple and exponential moving averages across and above the 30-day timeframe <a href="https://in.tradingview.com/symbols/NASDAQ-MSTR/technicals/">produced </a>a &#8220;Buy&#8221; signal for the stock.</p>
<p>A moving average calculates the average price of a financial instrument over a specific period. If the price is above the moving average, the trend is upward. If the price is below the moving average, the trend is downward. Traders use moving averages to identify entry and exit points.</p>
<p>Moreover, the Bull Bear Power indicator, which measures the strength of buyers and sellers, also signaled &#8220;Buy.&#8221;&nbsp;</p>
<p><strong>See Also:</strong><a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"><strong> </strong></a><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45740537/forget-dollars-willy-woo-says-bitcoin-will-be-priced-against-global-gdp-gold-used-to-be-that-money-btc-is-the-challenger"><strong>Forget Dollars: Willy Woo Says Bitcoin Will Be Priced Against Global GDP — &#8216;Gold Used To Be That Money, BTC Is The Challenger&#8217;</strong></a></p>
<p><strong>InvestXOS</strong>, an investment-focused X account, said MSTR was building "serious momentum" with a potential cup and handle formation on the daily chart.</p>
<p>"If it somehow runs past $400 psychological level, we might see a huge, huge b/o," the analyst said, projecting potential price targets at $541, $566 and $582.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">MicroStrategy <a href="https://twitter.com/search?q=%24MSTR&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$MSTR</a> is getting some serious momentum here with this potential cup &amp; handle formation on daily chart&#8230;. if it somehow runs pass 400 psychological level, we might see a huge huge b/o&#8230;. measured move points to 541 566 582 IF b/o does happen&#8230;. <a href="https://t.co/aIvHbWFiKf">pic.twitter.com/aIvHbWFiKf</a></p>
<p>&mdash; InvestXOS (@InvestXOS) <a href="https://twitter.com/InvestXOS/status/1930396429257695608?ref_src=twsrc%5Etfw">June 4, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>The momentum indicators, however, painted a different story. The Moving Average Convergence Divergence indicator, which plots the relationship between two moving averages—typically a 12-day and a 26-day exponential moving average—flashed "Sell" for MSTR.</p>
<p>Meanwhile, the Relative Strength Index indicator used for spotting overbought or oversold conditions showed a ‘Neutral&#8217; reading for the stock.</p>
<p>On the derivative front, MSTR's Put/Call Ratio was 0.85 as of this writing,&nbsp; <a href="https://fintel.io/sopt/us/mstr">according </a>to Fintel, indicating that bullish bets outnumbered bearish bets.</p>
<p><strong>Why It Matters</strong>: Strategy has been at the forefront of Bitcoin's corporate adoption, holding a BTC stockpile worth more than $60.8 billion as of this writing,&nbsp;<a href="https://bitcointreasuries.net/" target="_blank" rel="noreferrer noopener">according</a>&nbsp;to bitcointreasuries.net. </p>
<p>The stock has seen significant volatility in the last eight months or so. &nbsp;Strategy&#8217;s <a href="https://in.benzinga.com/crypto/cryptocurrency/25/06/45722106/strategy-and-metaplanet-deepen-bitcoin-exposure-with-over-190-million-in-fresh-buys-amid-105k-market-level#:~:text=treasury%20reserve%20asset.-,Strategy%20Inc.,billion%20at%20current%20market%20prices.">corporate strategy of using debt and equity</a> to accumulate Bitcoin makes it highly sensitive to the apex cryptocurrency&#8217;s price swings.&nbsp;</p>
<p><strong>Price Action</strong>:&nbsp; At the time of writing, BTC was exchanging hands at $104,905.99, up 0.88% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.&nbsp;</p>
<p>Shares of Strategy were up 0.41% in pre-market trading after closing 2.41% lower at $378.10 during Wednesday's regular trading session.</p>
<p>MSTR demonstrated a very high momentum score—a measure of the stock's relative strength based on its price movement patterns and volatility over multiple timeframes—as of this writing. Want to see which stocks outperformed MSTR in this metric? Visit <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge Stock Rankings</a>.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="447" height="186" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05060907/Screenshot-2025-06-05-153848.png" alt="" class="wp-image-939506" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05060907/Screenshot-2025-06-05-153848.png 447w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05060907/Screenshot-2025-06-05-153848-300x125.png 300w" sizes="(max-width: 447px) 100vw, 447px" /></a></figure></p>
<p><strong>Read Next:</strong><em>&nbsp;</em></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45739199/american-politicians-dont-believe-bitcoin-can-co-exist-peacefully-with-the-dollar-says-this-popular-btc-maximalist-heres-why"><strong>American Politicians Don&#8217;t Believe Bitcoin Can &#8216;Co-Exist Peacefully&#8217; With The Dollar, Says This Popular BTC Maximalist: Here&#8217;s Why</strong></a></li>
</ul>
<p><em>Photo courtesy: PJ McDonnell / Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Markets

$BTC

MSTR

Bitcoin Stock Strategy— Buy Or Sell? What Technicals Reveal For Michael Saylor's MSTR?

<p>Across the recent three months, 11 analysts have shared their insights on ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.45, with a high estimate of $35.00 and a low estimate of $22.00. Witnessing a positive shift, the current average has risen by 14.81% from the previous average price target of $23.91.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146492_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of ACADIA Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ACADIA Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for ACADIA Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>To gain a panoramic view of ACADIA Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ACAD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on ACADIA Pharmaceuticals analyst ratings.</strong></a></p>
<h2>Get to Know ACADIA Pharmaceuticals Better</h2>
<p>Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.</p>
<h3>ACADIA Pharmaceuticals's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, ACADIA Pharmaceuticals showcased positive performance, achieving a revenue growth rate of <strong>18.7%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>7.77%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> ACADIA Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>2.53%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> ACADIA Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.64%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.07</strong>, ACADIA Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

ACAD

The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts

<p>Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) has been analyzed by 3 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $6.5, a high estimate of $8.00, and a low estimate of $5.50. Marking an increase of 11.49%, the current average surpasses the previous average price target of $5.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146483_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Cipher Mining by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Chris Brendler</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.50</td>
<td>$5.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cipher Mining. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cipher Mining compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Cipher Mining's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Cipher Mining's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CIFR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Cipher Mining analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Cipher Mining</h2>
<p>Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.</p>
<h3>Cipher Mining's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Cipher Mining showcased positive performance, achieving a revenue growth rate of <strong>1.71%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Cipher Mining's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-79.61%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Cipher Mining's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-5.5%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Cipher Mining's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-4.41%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.08</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CIFR

Cipher Mining Stock: A Deep Dive Into Analyst Perspectives (3 Ratings)

<p>In the last three months, 8 analysts have published ratings on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $43.5, a high estimate of $56.00, and a low estimate of $38.00. This current average has increased by 7.09% from the previous average price target of $40.62. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146474_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Exelixis by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Exelixis's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Exelixis's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Exelixis analyst ratings.</strong></a></p>
<h2>Delving into Exelixis's Background</h2>
<p>Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.</p>
<h3>Understanding the Numbers: Exelixis's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Exelixis displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>30.62%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>28.74%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>7.3%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Exelixis's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.52%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Exelixis's debt-to-equity ratio is below the industry average at <strong>0.09</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EXEL

Analyst Expectations For Exelixis's Future

<p>13 analysts have expressed a variety of opinions on Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Lyft, revealing an average target of $17.85, a high estimate of $28.00, and a low estimate of $13.00. This upward trend is evident, with the current average reflecting a 1.77% increase from the previous average price target of $17.54.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146466_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Lyft. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lyft. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Lyft compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Lyft's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Lyft's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LYFT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Lyft analyst ratings.</strong></a></p>
<h2>Delving into Lyft's Background</h2>
<p>Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.</p>
<h3>Breaking Down Lyft's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Lyft showcased positive performance, achieving a revenue growth rate of <strong>13.54%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>0.18%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>0.32%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Lyft's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.05%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Lyft's debt-to-equity ratio surpasses industry norms, standing at <strong>1.41</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LYFT

The Analyst Verdict: Lyft In The Eyes Of 13 Experts

<p><strong>Regal Rexnord's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) short percent of float has risen 17.65% since its last report. The company recently reported that it has <strong>2.00 million shares sold short</strong>, which is 3.8% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.79 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Regal Rexnord Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146462_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Regal Rexnord has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Regal Rexnord's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Regal Rexnord's peer group average for short interest as a percentage of float is 10.71%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

Is the Market Bullish or Bearish on Regal Rexnord?

<p><strong>Compass Diversified Hldgs's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CODI#NYSE">CODI</a>) short percent of float has risen 28.77% since its last report. The company recently reported that it has <strong>690 thousand shares sold short</strong>, which is 0.94% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.0 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Compass Diversified Hldgs Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146457_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Compass Diversified Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Compass Diversified Hldgs's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Compass Diversified Hldgs's peer group average for short interest as a percentage of float is 6.11%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


CODI

How Is The Market Feeling About Compass Diversified Hldgs?

<p>Across the recent three months, 4 analysts have shared their insights on Hamilton Insurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Hamilton Insurance Group, revealing an average target of $22.5, a high estimate of $25.00, and a low estimate of $20.00. This current average has increased by 2.27% from the previous average price target of $22.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146454_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Hamilton Insurance Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Tommy McJoynt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hamilton Insurance Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hamilton Insurance Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Hamilton Insurance Group's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Hamilton Insurance Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Hamilton Insurance Group analyst ratings.</strong></a></p>
<h2>About Hamilton Insurance Group</h2>
<p>Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.</p>
<h3>Hamilton Insurance Group: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Hamilton Insurance Group's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>16.57%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Hamilton Insurance Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>10.35%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.42%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.0%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Hamilton Insurance Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.06</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 4 Analyst Projections For Hamilton Insurance Group

<p><strong>Bright Horizons Family's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) short percent of float has fallen 5.52% since its last report. The company recently reported that it has <strong>876 thousand shares sold short</strong>, which is 1.54% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.79 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Bright Horizons Family Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146452_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Bright Horizons Family has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Bright Horizons Family's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Bright Horizons Family's peer group average for short interest as a percentage of float is 4.43%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


BFAM

Is Bright Horizons Family Gaining or Losing Market Support?

<p>Financial giants have made a conspicuous bullish move on Applied Digital. Our analysis of options history for Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) revealed 28 unusual trades.</p>
<p>Delving into the details, we found 53% of traders were bullish, while 39% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $214,027, and 23 were calls, valued at $2,021,981.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $4.0 to $20.0 for Applied Digital over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Applied Digital stands at 4746.5, with a total volume reaching 59,781.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Applied Digital, situated within the strike price corridor from $4.0 to $20.0, throughout the last 30 days.</p>
<h3>Applied Digital 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146446_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>APLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$6.8</td>
<td>$6.7</td>
<td>$6.7</td>
<td>$7.00</td>
<td>$335.1K</td>
<td>8.4K</td>
<td>1.5K</td>
</tr>
<tr>
<td>APLD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$6.8</td>
<td>$6.7</td>
<td>$6.7</td>
<td>$7.00</td>
<td>$335.0K</td>
<td>8.4K</td>
<td>2.0K</td>
</tr>
<tr>
<td>APLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$2.77</td>
<td>$2.7</td>
<td>$2.71</td>
<td>$14.00</td>
<td>$135.2K</td>
<td>9.0K</td>
<td>4.4K</td>
</tr>
<tr>
<td>APLD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$2.7</td>
<td>$2.66</td>
<td>$2.7</td>
<td>$14.00</td>
<td>$135.0K</td>
<td>9.0K</td>
<td>5.4K</td>
</tr>
<tr>
<td>APLD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$2.46</td>
<td>$2.24</td>
<td>$2.25</td>
<td>$11.00</td>
<td>$135.0K</td>
<td>5.8K</td>
<td>3.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Applied Digital</h3>
<p>Applied Digital Corp is a designer, developer, and operator of next-generation digital infrastructure across North America. It provides digital infrastructure solutions and cloud services to industries like High-Performance Computing (HPC) and Artificial Intelligence (AI). The company operates in the following business segments; Data Center Hosting Business, Cloud Services Business, and HPC Hosting Business. The majority of its revenue is generated from the Data Center Hosting Business which operates data centers to provide energized space to crypto mining customers.</p>
<p>Following our analysis of the options activities associated with Applied Digital, we pivot to a closer look at the company's own performance.</p>
<h3>Applied Digital's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 150,234,717, the APLD's price is down by -1.4%, now at $13.06. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 83 days.</li>
</ul>
<h3>What The Experts Say On Applied Digital</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $13.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Applied Digital with a target price of $12.<br />
&#x2A; An analyst from HC Wainwright &amp; Co. persists with their Buy rating on Applied Digital, maintaining a target price of $12.<br />
&#x2A; An analyst from B. Riley Securities has decided to maintain their Buy rating on Applied Digital, which currently sits at a price target of $15.<br />
&#x2A; Reflecting concerns, an analyst from JMP Securities lowers its rating to Market Outperform with a new price target of $12.<br />
&#x2A; An analyst from JMP Securities has decided to maintain their Market Outperform rating on Applied Digital, which currently sits at a price target of $18. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Applied Digital with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

APLD

Check Out What Whales Are Doing With APLD

<p>5 analysts have shared their evaluations of Dave &amp; Buster's Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Dave &amp; Buster's Enter, revealing an average target of $26.0, a high estimate of $35.00, and a low estimate of $21.00. A decline of 23.53% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146446_0_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Dave &amp; Buster's Enter. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$22.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Andrew Strelzik</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Alton Stump</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Nicole Miller Regan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$21.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dave &amp; Buster's Enter. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dave &amp; Buster's Enter compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Dave &amp; Buster's Enter's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dave &amp; Buster's Enter's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PLAY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Dave &amp; Buster's Enter analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>About Dave &amp; Buster's Enter</h2>
<p>Dave &amp; Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.</p>
<h3>Financial Milestones: Dave &amp; Buster's Enter's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Dave &amp; Buster's Enter's revenue growth over a period of 3M has faced challenges. As of 31 January, 2025, the company experienced a revenue decline of approximately <strong>-10.77%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Dave &amp; Buster's Enter's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.74%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.99%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Dave &amp; Buster's Enter's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.23%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Dave &amp; Buster's Enter's debt-to-equity ratio surpasses industry norms, standing at <strong>21.53</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PLAY

A Glimpse Into The Expert Outlook On Dave & Buster's Enter Through 5 Analysts

<p>Financial giants have made a conspicuous bullish move on Coupang. Our analysis of options history for Coupang (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 66% of traders were bullish, while 22% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $450,836, and 5 were calls, valued at $216,864.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $26.0 and $37.0 for Coupang, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Coupang's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Coupang's whale activity within a strike price range from $26.0 to $37.0 in the last 30 days. </p>
<h3>Coupang Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146440_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CPNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$8.45</td>
<td>$8.3</td>
<td>$8.3</td>
<td>$37.00</td>
<td>$340.3K</td>
<td>410</td>
<td align="right">410</td>
</tr>
<tr>
<td>CPNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/13/25</td>
<td>$0.12</td>
<td>$0.09</td>
<td>$0.09</td>
<td>$30.00</td>
<td>$72.0K</td>
<td>936</td>
<td align="right">65</td>
</tr>
<tr>
<td>CPNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.26</td>
<td>$1.25</td>
<td>$1.26</td>
<td>$35.00</td>
<td>$55.3K</td>
<td>11.5K</td>
<td align="right">939</td>
</tr>
<tr>
<td>CPNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/18/26</td>
<td>$7.75</td>
<td>$7.55</td>
<td>$7.55</td>
<td>$35.00</td>
<td>$42.2K</td>
<td>0</td>
<td align="right">114</td>
</tr>
<tr>
<td>CPNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/18/26</td>
<td>$7.75</td>
<td>$7.65</td>
<td>$7.65</td>
<td>$35.00</td>
<td>$39.0K</td>
<td>0</td>
<td align="right">7</td>
</tr>
</tbody>
</table>
</p>
<h3>About Coupang</h3>
<p>Coupang is South Korea's largest e-commerce platform that sells both owned and third-party inventory. Headquartered in the US, Coupang operates e-commerce businesses mainly in South Korea and Taiwan. The company has built an integrated logistics network that covers the entirety of South Korea, with extensive fulfillment centers that ensure timely delivery, even for orders placed seconds before midnight. Outside of its bread-and-butter e-commerce business, Coupang has expanded into provision of its Rocket delivery services to third-party merchants (fulfillment and logistics by Coupang), online grocery delivery Rocket Fresh, online meal delivery (Eats), e-commerce in Taiwan, luxury e-commerce (Farfetch), and travel.</p>
<p>Following our analysis of the options activities associated with Coupang, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Coupang</h3>
<ul>
<li>With a trading volume of 3,257,577, the price of CPNG is up by 1.15%, reaching $28.68.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 61 days from now.</li>
</ul>
<h3>What The Experts Say On Coupang</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $36.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Coupang, targeting a price of $36. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Coupang with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


CPNG

Coupang Unusual Options Activity For June 05

<p>Deep-pocketed investors have adopted a bullish approach towards Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMZN usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 65 extraordinary options activities for Amazon.com. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 55% leaning bullish and 33% bearish. Among these notable options, 7 are puts, totaling $284,692, and 58 are calls, amounting to $5,638,601.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $175.0 and $250.0 for Amazon.com, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Amazon.com stands at 10993.46, with a total volume reaching 677,525.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Amazon.com, situated within the strike price corridor from $175.0 to $250.0, throughout the last 30 days.</p>
<h3>Amazon.com 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749146436_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/03/25</td>
<td>$37.75</td>
<td>$36.45</td>
<td>$37.15</td>
<td>$175.00</td>
<td>$876.7K</td>
<td>16</td>
<td>261</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/06/25</td>
<td>$36.85</td>
<td>$35.6</td>
<td>$36.18</td>
<td>$175.00</td>
<td>$853.8K</td>
<td>449</td>
<td>260</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/13/25</td>
<td>$6.35</td>
<td>$6.3</td>
<td>$6.3</td>
<td>$205.00</td>
<td>$327.6K</td>
<td>3.2K</td>
<td>1.4K</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$6.15</td>
<td>$6.05</td>
<td>$6.1</td>
<td>$235.00</td>
<td>$237.2K</td>
<td>5.3K</td>
<td>62</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/06/25</td>
<td>$4.35</td>
<td>$4.25</td>
<td>$4.3</td>
<td>$207.50</td>
<td>$215.8K</td>
<td>23.2K</td>
<td>4.4K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Amazon.com</h3>
<p>Amazon is the leading online retailer and marketplace for third party sellers. Retail related revenue represents approximately 75% of total, followed by Amazon Web Services' cloud computing, storage, database, and other offerings (15%), advertising services (5% to 10%), and other the remainder. International segments constitute 25% to 30% of Amazon's non-AWS sales, led by Germany, the United Kingdom, and Japan.</p>
<p>Having examined the options trading patterns of Amazon.com, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Amazon.com Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 32,393,757, with AMZN's price up by 1.07%, positioned at $209.45.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 56 days.</li>
</ul>
<h3>What Analysts Are Saying About Amazon.com</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $244.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on Amazon.com, maintaining a target price of $248.<br />
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Amazon.com, maintaining a target price of $240. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Amazon.com, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AMZN

A Closer Look at Amazon.com's Options Market Dynamics

<p>In the current session, the stock is trading at $76.47, after a <strong>0.05%</strong> increase. Over the past month, <strong>Sempra Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>)</strong> stock increased by <strong>0.92%</strong>, and in the past year, by <strong>1.51%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1749146420_0.png" alt="Past Year Chart" /></p>

<h3>How Does Sempra P/E Compare to Other Companies?</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Compared to the aggregate P/E ratio of the <strong>19.23</strong> in the Multi-Utilities industry, Sempra Inc. has a lower P/E ratio of <strong>16.8</strong>. Shareholders might be inclined to think that  the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1749146420_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

Price Over Earnings Overview: Sempra

<p><strong>Palantir Technologies Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) CEO <strong>Alex Karp</strong> denied claims on Thursday suggesting the company is aiding the government <a href="https://www.benzinga.com/markets/tech/25/06/45764231/palantir-says-it-doesnt-unlawfully-spy-on-americans-calls-report-alleging-use-by-trump-administration-for-surveillance-blatantly-untrue">in unlawful surveillance</a>.</p>
<p><strong>What Happened:</strong> The New York Times <a href="https://www.nytimes.com/2025/05/30/technology/trump-palantir-data-americans.html">reported</a> last week that the Trump Administration has tapped Palantir to collect data on Americans after President <strong>Donald Trump</strong> signed an executive order in March calling on the federal government to enable the sharing of data across agencies. </p>
<p>Thursday on CNBC&#8217;s &#8220;Squawk On The Street,&#8221; Karp refuted the report. </p>
<p>&#8220;The Palantir platform, despite what you might read at The New York Times, is actually the most secure, the hardest platform in the world to manipulate and change &#8230; If you wanted to use the Deep State to unlawfully surveil people, the last platform in the world you would pick is Palantir,&#8221; Karp said. </p>
<p>Palantir recently secured new <a href="https://www.benzinga.com/news/contracts/25/05/45702431/palantir-stock-gains-as-trump-expands-companys-role-in-us-government-agencies">contracts</a> with the Department of Homeland Security and the Pentagon. The New York Times report indicates that Palantir representatives are also in talks with the Social Security Administration and the Internal Revenue Service, and argues that wide government adoption of a single platform creates an easy path for Trump to combine data from different agencies.</p>
<p>Karp told CNBC that the article is &#8220;ridiculous&#8221; and shows that the publication doesn&#8217;t have proper technical knowledge. He noted that a random engineer could find 15 to 20 errors in the article in 90 seconds. </p>
<p>If you spent 10 minutes looking at the architecture of the Palantir platform, you would see how ridiculous the report is, he said.</p>
<p>&#8220;By the way, writing ridiculous sh&#x2A;&#x2A; in a highly-charged environment is dangerous, and The New York Times should take responsibility for the dangers they&#8217;re putting out in the world. There really are people that believe that crap,&#8221; the Palantir CEO said. </p>
<p>The New York Times report shows that Palantir is winning, he said, adding that U.S. government revenue is up 46% and U.S. commercial revenue is up 71%. He told CNBC that the company is seeing strong growth because the product is the best in the world. The Trump administration is buying the best, most secure product available, that&#8217;s cheaper and more efficient, and replacing older systems, he said. </p>
<p>&#8220;You know what we&#8217;re doing in the DOD, we&#8217;re scaring the bejeebers — I&#8217;m trying not to use the F word — out of our adversaries by making them scared at night &#8230; installing productized software that runs algorithms against data that&#8217;s been lawfully collected. And you can&#8217;t unlawfully use it in our platform, which is one of the main reasons people buy it and keep it,&#8221; Karp said. </p>
<p>Palantir said in its <a href="https://www.benzinga.com/news/earnings/25/05/45208000/palantir-q1-earnings-revenue-beat-eps-in-line-customer-count-up-39-company-raises-guidance-citing-surging-and-ferocious-growth">earnings report</a> last month that the company&#8217;s customer count grew 39% year-over-year and 8% on a quarter-over-quarter basis. Palantir raised its guidance for full-year U.S. commercial revenue, adjusted income from operations and adjusted free cash flow.&nbsp;</p>
<p><strong>PLTR Price Action: </strong><a href="https://www.benzinga.com/quote/PLTR" target="_blank" rel="noreferrer noopener">Palantir shares</a> are up approximately 64% year-to-date. The stock was down 5.58% at $122.67 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/45784629/cathie-wood-dumps-another-5-2-million-of-palantir-stock-amid-trump-administration-linked-surveillance-controversy"><strong>Cathie Wood Dumps Another $5.2 Million Of Palantir Stock Amid Trump Administration-Linked Surveillance Controversy</strong></a></li>
</ul>
<p><em>Photo: Sundry Photography/Shutterstock.</em></p>


Government

Tech

PLTR

Palantir CEO Alex Karp Refutes 'Ridiculous' Surveillance Reports, Says Company Is 'Winning'

<p><strong>Alvotech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) on Thursday collaborated with <strong>Dr. Reddy's Laboratories Ltd.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45788813/alvotech-and-dr-reddys-enter-into-collaboration-to-co-develop-biosimilar-candidate-to-keytruda-pem" rel="noreferrer noopener">for global markets</a>.</p>
<p><strong>Merck &amp; Co Inc's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) is indicated for numerous cancer types.</p>
<p>Keytruda's worldwide sales were $29.5 billion in 2024. The collaboration combines Dr. Reddy's and Alvotech's capabilities in biosimilars, speeding up the development process and extending the global reach for this biosimilar candidate.</p>
<p>Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities.</p>
<p><strong><em>Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a></em></strong></p>
<p>Subject to certain exceptions, each party will have the right to commercialize the product globally.</p>
<p>In May, the U.S. Food and Drug Administration (FDA) approved&nbsp;Teva and&nbsp;Alvotech Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic&nbsp;<strong>Johnson &amp; Johnson's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Stelara (ustekinumab)</a>.</p>
<p>In March, Alvotech&nbsp;announced the acquisition of<strong>&nbsp;</strong>R&amp;D operations of&nbsp;<strong>Xbrane Biopharma AB</strong> along with a biosimilar candidate, XB003, which is based on Cimzia (certolizumab pegol)&nbsp;for <a target="_blank" href="https://www.benzinga.com/news/mid-cap/25/03/44412592/alvotech-strengthens-biosimilar-portfolio-with-27-million-xbrane-rd-deal" rel="noreferrer noopener">around SEK275 million</a> (around $27 million).</p>
<p>The transaction includes a cash payment of SEK102.2 million at closing, along with the assumption of SEK172.8 million in debt and accounts payable.</p>
<p><strong>HSBC</strong> upgraded Dr Reddy's Laboratories from Hold to Buy and raised the price <a target="_blank" href="https://www.benzinga.com/quote/RDY/analyst-ratings" rel="noreferrer noopener">forecast from $14.44 to $16.9</a>.</p>
<h2 class="wp-block-heading">Stock Prediction For 2025 For Alvotech</h2>
<p>Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.</p>
<p>Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Alvotech, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Alvotech, the 200-day moving average sits at $11.44, according to <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, which is above the current price of $10.46. For more on charts and trend lines, <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">see a description here.</a></p>
<p>Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.</p>
<p><strong>Price Action:</strong> At the last check on Thursday, RDY stock was up 6.07% at $15.65, and ALVO stock was down 2.49% at $10.56.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><em><a href="https://www.benzinga.com/markets/biotech/25/06/45799258/gileads-hiv-pipeline-gains-traction-with-upcoming-fda-decision-for-hiv-1-drug" target="_blank" rel="noreferrer noopener">Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug</a></em></strong></li>
</ul>
<p><em>Photo by T. Schneider via Shutterstock</em></p>


Health Care

Contracts

Movers

General

ALVO

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

<p>If you're holding the <strong>VanEck Green Infrastructure ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNEW#NASDAQ">RNEW</a>) or <strong>VanEck HIP Sustainable Muni ETF</strong> (BATS:<a class="ticker" href="https://www.benzinga.com/stock/SMI#BATS">SMI</a>) funds, it's time to check your portfolio. VanEck is pulling the plug on <a href="https://www.benzinga.com/etfs">both products</a> later this month.</p>
<p>The deadline to trade these ETFs on the stock market is June 18. From there on, they&#8217;ll be delisted, and the remaining shareholders will be paid in cash around June 25, according to the net asset value of their investments.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45796685/nvidia-beats-microsoft-to-be-the-biggest-of-the-big-here-are-6-etfs-riding-its-trillion-dollar-rebound">Nvidia Beats Microsoft To Be The Biggest Of The Big: Here Are 6 ETFs Riding Its Trillion-Dollar Rebound</a></strong></p>
<h2 class="wp-block-heading">Why Is VanEck Doing This?</h2>
<p>In short: low performance and low demand. VanEck takes a regular look at its fund lineup to determine what&#8217;s hot and what&#8217;s not. These two sustainable-themed ETFs lacked sufficient assets or investor interest to remain in play.</p>
<p>The firm wasn&#8217;t specific, but it&#8217;s a common scenario— if a fund isn&#8217;t growing or gaining traction, even such large players as VanEck won&#8217;t retain it indefinitely.</p>
<h2 class="wp-block-heading">What This Means For You</h2>
<p>If you hold RNEW or SMI shares, you can trade them on your online brokerage site up to and including June 18 (your brokerage fees may apply). If you do not sell before then, you will be automatically paid out in cash on approximately June 25, the value of the fund at the time of liquidation.</p>
<p>You could also see a final income or capital gains distribution when the fund is closed.</p>
<p>For tax purposes, the liquidation will be treated as a capital gain or loss based on your cost basis. VanEck will distribute year-end tax information.</p>
<p>This action follows a broader trend in the ETF space. Asset managers are consolidating their product offerings, particularly when niche or thematic ETFs don&#8217;t attract sufficient investor capital. ESG investing isn&#8217;t disappearing, but it&#8217;s clear that not all &#8220;green&#8221; funds are meant to be permanent.</p>
<p><strong>Read Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45779722/global-x-debuts-covered-call-bitcoin-etf-aims-to-keep-volatility-in-check">Global X Debuts Covered Call Bitcoin ETF, Aims To Keep Volatility In Check</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


New ETFs

ETFs

RNEW

Semiconductor Manufacturing International

VanEck Shutters ESG ETFs RNEW, SMI Amid Low Demand For Green Investment Funds

<p>Monness, Crespi, Hardt  analyst Brian White   upgrades MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) from Neutral to Buy and announces $295 price target.</p>


Comments

Inspira Technologies Oxy

Inspira Technologies Oxy (IINN) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL